NASDAQ:DMTK

DermTech (DMTK) Stock Forecast, Price & News

$1.44

-0.04 (-2.70%)

(As of 09/29/2023 ET)

Compare

Today's Range: $1.44
▼
$1.54
50-Day Range: $1.44
▼
$3.53
52-Week Range: $1.44
▼
$6.44

Volume: 249,211 shs
Average Volume: 226,234 shs
Market Capitalization: $48.53 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.33

DermTech MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 339.8% Upside
$6.33 Price Target
Short Interest: Bearish
15.82% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.22
Based on 2 Articles This Week
Insider Trading: Selling Shares
$42,134 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.56) to ($2.65) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

630th out of 972 stocks

Medical Laboratories Industry

16th out of 25 stocks

3.4

Analyst's Opinion

Consensus Rating
DermTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.33, DermTech has a forecasted upside of 339.8% from its current price of $1.44.
Amount of Analyst Coverage
DermTech has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
15.82% of the float of DermTech has been sold short.
Short Interest Ratio / Days to Cover
DermTech has a short interest ratio ("days to cover") of 17.1, which indicates bearish sentiment.
Change versus previous month
Short interest in DermTech has recently decreased by 2.07%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
DermTech does not currently pay a dividend.
Dividend Growth
DermTech does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DMTK.

3.5

News and Social Media Coverage

News Sentiment
DermTech has a news sentiment score of 1.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for DermTech this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for DMTK on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
3 people have added DermTech to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, DermTech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,134.00 in company stock.
Percentage Held by Insiders
Only 5.10% of the stock of DermTech is held by insiders.
Percentage Held by Institutions
Only 27.81% of the stock of DermTech is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for DermTech are expected to grow in the coming year, from ($3.56) to ($2.65) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of DermTech is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of DermTech is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
DermTech has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About DermTech (NASDAQ:DMTK) Stock

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer and inflammatory diseases in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

DMTK Price History

30 days | 90 days | 365 days | Advanced Chart

DMTK Stock News Headlines

September 25, 2023 | benzinga.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DermTech, Inc. - DMTK

September 21, 2023 | finance.yahoo.com

DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4)

October 1, 2023 | Legacy Research (Ad)

Elon Did It Again: This Could be Bigger than Tesla

Love him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.

September 19, 2023 | uk.style.yahoo.com

One penny stock I’m having second thoughts about

September 19, 2023 | finance.yahoo.com

DermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT)

September 18, 2023 | technews.tmcnet.com

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of DermTech, Inc. (DMTK) on Behalf of Investors

September 18, 2023 | stockhouse.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of DermTech, Inc. (DMTK) on Behalf of Investors

September 15, 2023 | benzinga.com

The Law Offices of Frank R. Cruz Announces Investigation of DermTech, Inc. (DMTK) on Behalf of Investors

October 1, 2023 | Legacy Research (Ad)

Elon Did It Again: This Could be Bigger than Tesla

September 13, 2023 | finance.yahoo.com

Insider Sell: DermTech Inc CFO Kevin Sun Sells 9,616 Shares

September 11, 2023 | finance.yahoo.com

DermTech Appoints Mark Aguillard as Chief Commercial Officer

August 9, 2023 | finance.yahoo.com

DermTech (NASDAQ:DMTK) Will Have To Spend Its Cash Wisely

August 8, 2023 | msn.com

BTIG Maintains DermTech (DMTK) Buy Recommendation

August 3, 2023 | finance.yahoo.com

DermTech Reports Second-Quarter 2023 Financial Results

August 3, 2023 | markets.businessinsider.com

DermTech International Registered earnings: here's what Wall Street expects

July 31, 2023 | markets.businessinsider.com

DermTech (DMTK) Gets a Buy from Craig-Hallum

July 19, 2023 | finance.yahoo.com

DermTech Announces Favorable Coverage Policy With Blues Plan in Michigan for the Foundational Assay of Its DermTech Melanoma Test (DMT)

July 17, 2023 | finance.yahoo.com

DermTech Announces Release Date for Second-Quarter 2023 Financial Results

July 13, 2023 | finance.yahoo.com

DermTech, Inc. (NASDAQ:DMTK) surges 21%; retail investors who own 59% shares profited along with institutions

July 12, 2023 | finance.yahoo.com

DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)

July 7, 2023 | msn.com

San Diego’s DermTech trims staff to conserve cash as it pushes scalpel-free diagnostic test for melanoma

June 29, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: DermTech (DMTK) and NeuroPace (NPCE)

June 29, 2023 | msn.com

Why DermTech Shares Are Rising Today

June 29, 2023 | msn.com

DMTK Surges after Restructuring Program

June 28, 2023 | msn.com

DermTech announces restructuring to focus on its Melanoma Test, lays off 15% of workforce

June 28, 2023 | finance.yahoo.com

DermTech Announces Restructuring to Prioritize Growth Opportunities and Streamline Operations

June 14, 2023 | finance.yahoo.com

ECRI Completes Evaluation of the Pigmented Lesion Assay (PLA), the Foundational Assay for the DermTech Melanoma Test (DMT)

See More Headlines

Receive DMTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DermTech and its competitors with MarketBeat's FREE daily newsletter.

DMTK Company Calendar

Last Earnings: 8/03/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DMTK
CUSIP: N/A
CIK: 1651944
Web: www.dermtech.com
Phone: (858) 450-4222
Fax: N/A
Employees: 278
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.33
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $5.00
Forecasted Upside/Downside: +339.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.90)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-116,680,000.00
Net Margins: -853.02%
Pretax Margin: -853.02%
Return on Equity: -99.14%
Return on Assets: -65.52%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.85
Quick Ratio: 5.77

Sales & Book Value

Annual Sales: $14.52 million
Price / Sales: 3.34
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.38 per share
Price / Book: 0.33

Miscellaneous

Outstanding Shares: 33,700,000
Free Float: 31,981,000
Market Cap: $48.53 million
Optionable: Not Optionable
Beta: 2.22

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Kevin Sun M.B.A. (Age 45)
CFO, Treasurer & Sec.
Comp: $461.92k

Ms. Claudia Ibarra (Age 61)
Chief Operating Officer
Comp: $414.09k

Mr. Ray Akhavan Esq. (Age 54)
J.D., Gen. Counsel
Comp: $413.06k

Mr. Bret Christensen (Age 52)
Pres, CEO & Director

Mr. William W. Zondler
Chief Information Officer

Mr. Steve E. Kunszabo
Sr. Director of Investor Relations

Ms. Jennifer Eilemberg
Chief Compliance Officer

Mr. Ray Bassi
VP of Sales

Dr. Burkhard Jansen M.D. (Age 57)
Chief Medical Affairs Officer

Mr. Daniel Visage
Sr. VP of Payer Access

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DMTK Stock - Frequently Asked Questions

Should I buy or sell DermTech stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DMTK shares.
View DMTK analyst ratings or view top-rated stocks.
What is DermTech's stock price forecast for 2023?: 4 Wall Street research analysts have issued 12-month price targets for DermTech's shares. Their DMTK share price forecasts range from $5.00 to $8.00. On average, they anticipate the company's stock price to reach $6.33 in the next year. This suggests a possible upside of 339.8% from the stock's current price.
View analysts price targets for DMTK or view top-rated stocks among Wall Street analysts.
How have DMTK shares performed in 2023?: DermTech's stock was trading at $1.77 at the start of the year. Since then, DMTK stock has decreased by 18.6% and is now trading at $1.44.
View the best growth stocks for 2023 here.
When is DermTech's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our DMTK earnings forecast.
How were DermTech's earnings last quarter?: DermTech, Inc. (NASDAQ:DMTK) issued its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.99) earnings per share for the quarter, missing the consensus estimate of ($0.95) by $0.04. The firm had revenue of $3.98 million for the quarter, compared to analyst estimates of $3.55 million. DermTech had a negative trailing twelve-month return on equity of 99.14% and a negative net margin of 853.02%.
What other stocks do shareholders of DermTech own?: Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include Pfizer (PFE), CrowdStrike (CRWD), DocuSign (DOCU), ONEOK (OKE), Intel (INTC), U.S. Xpress Enterprises (USX), Valero Energy (VLO), Hello Group (MOMO), AVEO Pharmaceuticals (AVEO) and Camping World (CWH).

What is DermTech's stock symbol?: DermTech trades on the NASDAQ under the ticker symbol "DMTK."
How do I buy shares of DermTech?: Shares of DMTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is DermTech's stock price today?: One share of DMTK stock can currently be purchased for approximately $1.44.
How much money does DermTech make?: DermTech (NASDAQ:DMTK) has a market capitalization of $48.53 million and generates $14.52 million in revenue each year. The company earns $-116,680,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis.
How many employees does DermTech have?: The company employs 278 workers across the globe.
How can I contact DermTech?: DermTech's mailing address is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. The official website for the company is www.dermtech.com. The company can be reached via phone at (858) 450-4222 or via email at investorrelations@dermtech.com.

This page (NASDAQ:DMTK) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial